letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12...4567891011121314...100101»
  • ||||||||||  zotatifin (eFT226) / eFFECTOR Therap, Verzenio (abemaciclib) / Eli Lilly
    Enrollment change, Trial completion date, Trial primary completion date, Combination therapy:  RESOLVE: Abemaciclib + Letrozole +/- Metformin or Zotatifin in Endometrial or Low-Grade Serous Ovarian Cancer (clinicaltrials.gov) -  Jun 11, 2024   
    P2,  N=130, Recruiting, 
    Use of abemaciclib for treatment of high-risk EBC was described, which could help inform patient selection and treatment patterns. N=60 --> 130 | Trial completion date: May 2026 --> Aug 2029 | Trial primary completion date: May 2024 --> Aug 2026
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Estrogen stimulates fetal vascular endothelial growth factor expression and microvascularization. (Pubmed Central) -  Jun 8, 2024   
    The reduction in fetal skeletal muscle microvascularization was associated with a 52% decline (P = 0.02) in acetylcholine-induced brachial artery dilation and 23% increase (P = 0.01) in mean arterial blood pressure in adult progeny of letrozole-treated baboons and restored to normal by letrozole plus estradiol. The present study indicates that estrogen upregulates skeletal muscle VEGF expression and systemic microvessel development within the fetus as an essential programming event critical for ontogenesis of systemic vascular function and insulin sensitivity/glucose homeostasis after birth in primate offspring.
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    Trial completion date, Trial primary completion date:  Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer (clinicaltrials.gov) -  Jun 7, 2024   
    P2,  N=32, Recruiting, 
    The present study indicates that estrogen upregulates skeletal muscle VEGF expression and systemic microvessel development within the fetus as an essential programming event critical for ontogenesis of systemic vascular function and insulin sensitivity/glucose homeostasis after birth in primate offspring. Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jul 2024 --> Jul 2025
  • ||||||||||  metformin / Generic mfg., letrozole / Generic mfg.
    Preclinical, Journal:  Gonadotropin upregulates intraovarian calpains-1 and -2 during ovarian follicular recruitment in the SD rat model. (Pubmed Central) -  Jun 6, 2024   
    Letrozole and metformin separately increased the expression level of calpains-1 and -2 in the hGCs during luteinization. In conclusion, the expression levels of calpains -1 and -2 are increased with ovarian follicular recruitment by PMSG and calpain-1 is decreased in the PCOS condition, and letrozole and metformin upregulate the expression of calpains-1 and -2 during luteinization in the hGCs possibly via E2 action.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Kisqali (ribociclib) / Novartis, Perjeta (pertuzumab) / Roche
    Enrollment closed, Trial completion date, Trial primary completion date:  Detect V / CHEVENDO (Chemo vs. Endo) (clinicaltrials.gov) -  Jun 3, 2024   
    P3,  N=271, Active, not recruiting, 
    Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial completion date: Nov 2024 --> Jan 2025 | Trial primary completion date: Sep 2024 --> Jan 2025
  • ||||||||||  letrozole / Generic mfg., thyroxine / Generic mfg.
    Trial completion date, Trial primary completion date:  Best Treatment for Women With Both (Polycystic Ovary Syndrome) PCOS and Subclinical Hypothyroidism (clinicaltrials.gov) -  Jun 3, 2024   
    P=N/A,  N=200, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Nov 2024 --> Jan 2025 | Trial primary completion date: Sep 2024 --> Jan 2025 Trial completion date: May 2024 --> May 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Evaluating the potential of daily intake of polystyrene microplastics via drinking water in inducing PCOS and its ovarian fibrosis progression using female zebrafish. (Pubmed Central) -  Jun 3, 2024   
    Resembling letrozole-PCOS zebrafish model, daily intake of polystyrene-microplastics displayed hallmark PCOS pathophysiology; like excess body weight and %Gonadosomatic index, decreased Follicle Stimulating Hormone and ?-estradiol, increased Luteinising Hormone, brain and ovarian Testosterone (39.3% and 75% respectively)...Polystyrene microplastics played vital role in inducing PCOS further enhancing oxidative stress, which positively influences inflammation and aggravate ovarian mitophagy, shedding light on its ability to harshen PCOS into ovarian fibrosis, which is characterized by collagen deposition and upregulation of pro-fibrogenic biomarker genes. These findings illustrate the potential of daily microplastics intake via drinking water in triggering PCOS and its progression to ovarian fibrosis.
  • ||||||||||  AVZO-021 / Avenzo Therap
    Enrollment change, Trial completion date, Trial primary completion date:  ARTS-021-1001: Study of AVZO-021 in Patients with Advanced Solid Tumors (clinicaltrials.gov) -  May 29, 2024   
    P1/2,  N=430, Recruiting, 
    Because live births were significantly higher when progesterone ranged from 1.0 to <1.5?ng/ml, further study is needed to clarify whether this progesterone range may truly represent a prognostic indicator in OS-IUI cycles. N=192 --> 430 | Trial completion date: Apr 2026 --> Jan 2030 | Trial primary completion date: Oct 2025 --> Jan 2028
  • ||||||||||  ketoconazole / Generic mfg., letrozole / Generic mfg.
    Journal:  Identification of New Substrates and Inhibitors of Human CYP2A7. (Pubmed Central) -  May 25, 2024   
    We found several new proluciferin probe substrates for both enzyme variants (we also performed in silico studies to understand the activity difference between CYP2A7-WT and CYP2A7*1 on specific substrates), and we show that while they do not act on the standard CYP2A6 substrates nicotine, coumarin, or 7-ethoxycoumarin, both can hydroxylate diclofenac (as can CYP2A6). Moreover, we found ketoconazole, 1-benzylimidazole, and letrozole to be CYP2A7 inhibitors.
  • ||||||||||  letrozole / Generic mfg.
    Journal:  YKL-40 Knockdown Decreases Oxidative Stress Damage in Ovarian Granulosa Cells. (Pubmed Central) -  May 23, 2024   
    YKL-40 levels were elevated in the follicular fluids of women with PCOS and the ovaries of rats with PCOS. YKL-40 expression can be induced by oxidative stress, and YKL-40 knockdown can decrease oxidative stress damage in OGCs.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Ibrance (palbociclib) / Pfizer
    Enrollment closed, Phase classification, Enrollment change, Metastases:  PALVEN: Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer (clinicaltrials.gov) -  May 22, 2024   
    P1,  N=17, Active, not recruiting, 
    YKL-40 expression can be induced by oxidative stress, and YKL-40 knockdown can decrease oxidative stress damage in OGCs. Recruiting --> Active, not recruiting | Phase classification: P1b --> P1 | N=36 --> 17
  • ||||||||||  letrozole / Generic mfg.
    Enrollment open:  PLUM: Prescription of Letrozole for Uterine Myoma (clinicaltrials.gov) -  May 19, 2024   
    P4,  N=140, Recruiting, 
    Trial completion date: Dec 2024 --> Apr 2025 Not yet recruiting --> Recruiting
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    Trial completion date, Trial primary completion date:  Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib (clinicaltrials.gov) -  May 19, 2024   
    P2,  N=60, Recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Apr 2025 --> Apr 2028 | Trial primary completion date: Apr 2024 --> Apr 2026
  • ||||||||||  letrozole / Generic mfg.
    Preclinical, Journal:  Apelin receptor modulation mitigates letrozole-induced polycystic ovarian pathogenesis in mice. (Pubmed Central) -  May 19, 2024   
    Therefore, apelin13 (which down-regulates APJ) and ML221 (an APJ antagonist) may have suppressed APJ signalling, which would account for our findings on the mitigation of polycystic ovarian syndrome. In conclusion, both apelin13 and ML221 mediated mitigation have different mechanisms, which need further investigation.
  • ||||||||||  letrozole / Generic mfg.
    Journal:  The role of neuroestrogens in the estrogen-induced gonadotropin surge in male monkeys. (Pubmed Central) -  May 18, 2024   
    Unlike in rodents, it is known that a high dose of estrogen treatment can result in the LH surge in ORX male rhesus monkeys. Results that the administration of the aromatase inhibitor, letrozole, failed to attenuate the estrogen-induced LH surge, suggest that unlike in ovariectomized females, neuroestrogens do not play a role in the LH surge experimentally induced by the exogenous estrogen treatment in ORX male monkeys.
  • ||||||||||  letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
    Journal:  Cytochrome P450 enzymes as drug targets in human disease. (Pubmed Central) -  May 16, 2024   
    Significance Statement The selective inhibition of certain P450s that have major physiological functions has been shown to be very efficacious in certain human diseases. In several cases the search for better drugs continues.
  • ||||||||||  tagtociclib (PF-07104091) / Pfizer
    Enrollment closed, Enrollment change, Trial completion date, Combination therapy:  PF-07104091 as a Single Agent and in Combination Therapy (clinicaltrials.gov) -  May 16, 2024   
    P1/2,  N=154, Active, not recruiting, 
    Further studies are required to validate emerging data that ANA1 results in IES for some patients and to determine the clinical benefit of switching to ANA10 or an alternative AI. Recruiting --> Active, not recruiting | N=320 --> 154 | Trial completion date: Jan 2026 --> Mar 2025
  • ||||||||||  letrozole / Generic mfg.
    Enrollment change, Trial termination:  Letrozole in Patients With Hepatopulmonary Syndrome (clinicaltrials.gov) -  May 13, 2024   
    P2,  N=1, Terminated, 
    Trial completion date: Mar 2024 --> Oct 2032 N=20 --> 1 | Recruiting --> Terminated; Low Recruitment Numbers
  • ||||||||||  letrozole / Generic mfg.
    Preclinical, Journal:  Enhancing the efficacy of letrozole-loaded PEGylated nanoliposomes against breast cancer cells: In vitro study. (Pubmed Central) -  May 10, 2024   
    The results of apoptosis and cell cycle arrest using flow cytometry show that Lipo-Let-PEG caused the most significant increase in apoptotic rates and cell cycle arrest in cancer cells compared to other treated groups. In conclusion, Lipo-Let-PEG can be used as an anticancer agent by arresting cell cycle progression and inducing apoptosis, which can be applied in future studies to prevent breast cancer development.